At 42.2x sales and 63.7x book with no P/E, no forward P/E, and a deeply negative Altman Z-Score of -4.3, this is not a growth story — it is a balance sheet stress case being priced like a premium disruptor. The absence of earnings combined with EPS of -6.9 and expected EPS of -2.55 next year signals continued losses with no valuation anchor. A 137.50% return on equity looks optically explosive but is functionally distorted by a -705.80% debt-to-equity structure, which indicates negative equity dynamics rather than operational excellence. The market cap of $840M versus a consensus target price of 1.67 and a weak 24.90% consensus rating suggests limited institutional conviction. This is a highly speculative equity priced on future optionality while flashing multiple financial distress signals.